Infants fed formula milk gain weight at a more rapid rate compared with those fed breast milk, according to data from the CHILD* birth cohort. The favourable effect of breast milk on anthropometric outcomes is dose dependent but slightly attenuated when babies are fed via a bottle than when nursed directly.
Hybrid closed-loop insulin therapy in patients with suboptimally controlled type 1 diabetes (T1D) helps to keep their sugar levels within range, a 12-week multicentre, multinational trial has shown, supporting the utility of closed-loop technology in clinical practice.
The GLP-1* receptor agonist lixisenatide may slow the progression of micro- and macroalbuminuria in patients with type 2 diabetes (T2D) and acute coronary syndrome, based on an exploratory analysis of the ELIXA** trial presented at EASD 2018.
Treatment with twincretin, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1 receptor agonist combined into a single drug (LY3298176), not only reduced blood glucose in patients with type 2 diabetes (T2D) – it came with an added benefit of weight loss, with no increase in hypoglycaemia in a phase IIb trial.
Daily consumption of the Kaempferia parviflora extract (KPE) from the KP Wall. ex Baker plant, also known as black ginger or Krachai-Dam, effectively reduced abdominal fat, offering a natural alternative that could prevent obesity, according to a Japanese study.
Treatment with the DPP-4* inhibitor linagliptin in addition to the standard of care has no impact on heart failure, cardiovascular (CV), or renal events compared with standard of care alone in patients with type 2 diabetes (T2D) who had a very high risk of CV events and/or kidney disease progression, according to the CARMELINA** postmarketing outcomes study, thus providing reassurance on the CV safety of at least one member of the drug class.
Long-term therapy with testosterone undecanoate (TU) in hypogonadal men with type 2 diabetes (T2D) may improve glycaemic control and reverse disease progression, as well as induce significant weight loss, according to a study presented at EASD 2018.
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.